Advertisement
Advertisement
MCRB
Seres Therapeutics, Inc.
1.98
USDSponsored
-0.11
-5.26%
Nov 06, 15:59 UTC -5
Closed
After-Market
2.10
+0.12
+6.16%
Seres Therapeutics, Inc. (MCRB) Earnings
MCRB Earnings Reports
Positive Surprise Ratio
MCRB beat 21 of 43 last estimates.
49%
Next Report
Date of Next Report
Mar 10, 2027
Estimate for Q4 26 (Revenue/ EPS)
$6.48M
/-$1.03
Implied change from Q3 26 (Revenue/ EPS)
--
/--
Implied change from Q4 25 (Revenue/ EPS)
+1378.77%
/-42.13%
Seres Therapeutics, Inc. earnings per share and revenue
On Nov 03, 2026, MCRB reported earnings of -- USD per share (EPS) for Q3 26, -- the estimate of -1.02 USD, resulting in a --% surprise. Revenue reached --, compared to an expected 6.48 million, with a --% difference.
Looking ahead to Q4 26, -- analysts forecast an EPS of -1.03 USD, with revenue projected to reach 6.48 million USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
INmune Bio Inc. Common stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.14
Actual
-$0.17
Surprise
-13.64%
Moderna, Inc. Common Stock
Report Date
Nov 06, 2026 For Q3 26
Estimate
-$1.27
Actual
$0.38
Surprise
+129.79%
Vera Therapeutics, Inc. Class A Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$1.65
Actual
-$1.30
Surprise
+21.33%
Novavax Inc
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.34
Actual
-$0.19
Surprise
+44.56%
Eton Pharmaceutcials, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
$0.31
Actual
$1.06
Surprise
+232.50%
Castle Biosciences, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.37
Actual
-$0.13
Surprise
+65.32%
Monte Rosa Therapeutics, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.29
Actual
$0.03
Surprise
+110.09%
PUMA BIOTECHNOLOGY INC
Report Date
Nov 05, 2026 For Q3 26
Estimate
$0.09
Actual
$0.15
Surprise
+63.40%
Allogene Therapeutics, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.15
Actual
-$0.15
Surprise
+0.33%
Arcturus Therapeutics Holdings Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.69
Actual
-$0.26
Surprise
+62.44%
FAQ
What were Seres Therapeutics, Inc.'s earnings and revenue for the latest quarter Q3 2026?
For Q3 2026, Seres Therapeutics, Inc. reported EPS of --, missing estimates by --, and revenue of --, -- -- expectations.
How did the market react to Seres Therapeutics, Inc.'s Q3 2026 earnings?
The stock price moved -- --, changed from -- before the earnings release to -- the day after.
When is Seres Therapeutics, Inc. expected to report next?
The next earning report is scheduled for Mar 10, 2027.
What are the forecasts for Seres Therapeutics, Inc.'s next earnings report?
Based on --
analysts, Seres Therapeutics, Inc. is expected to report EPS of -$1.03 and revenue of $6.48M for Q4 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.